BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 36116169)

  • 1. Safety and efficacy of anlotinib in combination with standard chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A multi-center, prospective study (ACTION-2).
    Zhang W; Deng P; Kong T; Zhang B; Qian F; Dong Y; Chen Y; Chen L; Liu D; Zhang Y; Yang H; Han B
    Lung Cancer; 2022 Nov; 173():43-48. PubMed ID: 36116169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study.
    Kong T; Chen L; Zhao X; Duan F; Zhou H; Wang L; Liu D
    Invest New Drugs; 2022 Oct; 40(5):1095-1105. PubMed ID: 35788937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of anlotinib combined with etoposide and platinum-based regimens in the first-line treatment of extensive-stage small cell lung cancer.
    Liu C; Liao J; Wu X; Zhao X; Sun S; Wang H; Hu Z; Zhang Y; Yu H; Wang J
    Thorac Cancer; 2022 May; 13(10):1463-1470. PubMed ID: 35388976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic effectiveness of anlotinib combined with etoposide in extensive-stage small-cell lung cancer: a single-arm, phase II trial.
    Wu Y; Zhou X; Zhao W; Wang Q; Han Z; Wang L; Zhou W; Zhou T; Song H; Chen Y; Yang K; Shi L; Pan B; Guo R; Zhou G; Jiang F; Feng J; Shen B
    Invest New Drugs; 2023 Dec; 41(6):825-833. PubMed ID: 37837490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anlotinib plus platinum-etoposide as a first-line treatment for extensive-stage small cell lung cancer: A single-arm trial.
    Deng P; Hu C; Chen C; Cao L; Gu Q; An J; Qin L; Li M; He B; Jiang J; Yang H
    Cancer Med; 2022 Oct; 11(19):3563-3571. PubMed ID: 35526266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis.
    Wang Y; Li L; Hu J; Zhao Y; Yan H; Gao M; Yang X; Zhang X; Ma J; Dai G
    BMC Cancer; 2023 Dec; 23(1):1196. PubMed ID: 38057736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer.
    Glisson B; Besse B; Dols MC; Dubey S; Schupp M; Jain R; Jiang Y; Menon H; Nackaerts K; Orlov S; Paz-Ares L; Ramlau R; Tang R; Zhang Y; Zhu M
    Clin Lung Cancer; 2017 Nov; 18(6):615-625.e8. PubMed ID: 28601388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
    Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
    Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Efficacy and Safety of Anlotinib Plus Etoposide with Cisplatin/Carboplatin in the First-Line Treatment of Lung Cancer: A Phase II Clinical Study.
    Lv XM; Liu Y; Feng Y; Liang HL; Zhi WW
    J Cancer; 2024; 15(11):3539-3546. PubMed ID: 38817880
    [No Abstract]   [Full Text] [Related]  

  • 10. Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer.
    Langer CJ; Albert I; Ross HJ; Kovacs P; Blakely LJ; Pajkos G; Somfay A; Zatloukal P; Kazarnowicz A; Moezi MM; Schreeder MT; Schnyder J; Ao-Baslock A; Pathak AK; Berger MS;
    Lung Cancer; 2014 Sep; 85(3):420-8. PubMed ID: 24997137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer.
    Reck M; Horn L; Novello S; Barlesi F; Albert I; Juhász E; Kowalski D; Robinet G; Cadranel J; Bidoli P; Chung J; Fritsch A; Drews U; Wagner A; Govindan R
    J Thorac Oncol; 2019 Apr; 14(4):701-711. PubMed ID: 30677506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of fluzoparib combined with anlotinib in extensive stage small cell lung cancer after first-line platinum-based chemotherapy: a multi-center, single-arm prospective phase II clinical study (STAMP study).
    Li D; Huang Z; Zhong J; Lin L; Zhang G; Zhuang W; Liu Z
    BMC Cancer; 2023 Aug; 23(1):753. PubMed ID: 37580661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
    Paz-Ares L; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Kazarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Shire N; Jiang H; Goldman JW;
    Lancet; 2019 Nov; 394(10212):1929-1939. PubMed ID: 31590988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world study.
    Zheng HR; Jiang AM; Gao H; Liu N; Zheng XQ; Fu X; Ruan ZP; Tian T; Liang X; Yao Y
    Front Oncol; 2022; 12():894835. PubMed ID: 36203439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.
    Reck M; Luft A; Szczesna A; Havel L; Kim SW; Akerley W; Pietanza MC; Wu YL; Zielinski C; Thomas M; Felip E; Gold K; Horn L; Aerts J; Nakagawa K; Lorigan P; Pieters A; Kong Sanchez T; Fairchild J; Spigel D
    J Clin Oncol; 2016 Nov; 34(31):3740-3748. PubMed ID: 27458307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of novel immune checkpoint inhibitor-based combinations versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer: A network meta-analysis.
    Yang C; Xuan T; Gong Q; Dai X; Wang C; Zhang R; Zhao W; Wang J; Yue W; Li J
    Thorac Cancer; 2024 May; 15(15):1246-1262. PubMed ID: 38623838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis.
    Jiang S; Huang L; Zhen H; Jin P; Wang J; Hu Z
    BMC Cancer; 2021 Dec; 21(1):1308. PubMed ID: 34876060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer.
    Gao X; Peng L; Zhang L; Huang K; Yi C; Li B; Meng X; Li J
    J Cancer Res Clin Oncol; 2022 Oct; 148(10):2661-2671. PubMed ID: 34748028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC.
    Arriola E; Wheater M; Galea I; Cross N; Maishman T; Hamid D; Stanton L; Cave J; Geldart T; Mulatero C; Potter V; Danson S; Woll PJ; Griffiths R; Nolan L; Ottensmeier C
    J Thorac Oncol; 2016 Sep; 11(9):1511-21. PubMed ID: 27296105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer.
    Nogami N; Tokito T; Zenke Y; Satouchi M; Seto T; Saka H; Ohtani J; Han S; Noguchi K; Nishio M
    Invest New Drugs; 2024 Feb; 42(1):136-144. PubMed ID: 38300341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.